000			03918nam a22003735i 4500
001			100647
003			ESmaUEC
005			20230102113005.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			180403s2018 gw | s |||| 0|eng d
020			_a9783319764962 _9
024	7		_a10.1007/978-3-319-76496-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
050		4	_aRC924.5.L85 2018 EB
245	1	0	_aNeuropsychiatric Systemic Lupus Erythematosus : _bPathogenesis, Clinical Aspects and Treatment _cedited by Shunsei Hirohata.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2018
300			_a1 recurso en línea (VIII, 189 páginas 24 ilustraciones,12 ilustraciones a color)
336			_aTexto _btxt _2rdacontent
347			_atext file _bPDF _2
505	0		_a1 Epidemiology -- 2 Genetics -- 3 Immunology and pathogenesis -- 4 Pathology -- 5 Clinical Features -- 6 Cytokine -- 7 Diagnosis and Differential diagnosis -- 8 Imaging of NPSLE -- 9 Psychiatric symptoms -- 10 Treatment -- 11 Promising treatment alternatives -- 12 Prognosis.
520	3		_aNeuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most recalcitrant complications of the disease. According to the 1999 ACR nomenclature and case definitions, diffuse psychiatric/neuropsychological syndromes in NPSLE (anxiety disorder, acute confusional state, cognitive dysfunction, mood disorder, psychosis) (diffuse NPSLE) present psychiatric manifestations unlike neurologic syndromes (focal NPSLE) originating from focal CNS lesions, such as cerebrovascular disease, demyelinating syndrome, headache, aseptic meningitis, chorea, seizures and myelopathy. A number of studies have reported that diffuse NPSLE is usually associated with the presence of autoantibodies against neuronal cells in serum as well as in cerebrospinal fluid (CSF). Moreover, IL-6 has been shown to be elevated in CSF of patients with diffuse NPSLE. Recently, it has been demonstrated that the severity of blood-brain barrier damages plays a crucial role in the development of acute confusional state, the severest form of diffuse NPSLE through the accelerated entry of larger amounts of autoantibodies to NMDA receptor subunit NR2 into the CNS. Since the importance of autoantibodies in the NPSLE has been now evident, such an aggressive treatment, especially B cell depleting therapy, would make sense in that it would reduce the levels of pathogenic autoantibodies, leading to a better prognosis of NPSLE. As far as we know, no single book specifically dedicated to NPSLE alone has been published as yet. As mentioned above, NPSLE constitutes a vastly expanding field of research with increasing numbers of papers published annually. Therefore, we believe that an effort to collect and critically review these publications is invaluable. Such an effort will provide an important contribution to basic researchers as well as clinicians working in the field of neurology, rheumatology, psychiatry and internal medicine fields.
650		7	_aLupus eritematoso sistémico _9667662 _2embne
650		7	_aInmunología _2embne _9138330
700	1		_aHirohata, Shunsei _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/nb2016002806 _1http://viaf.org/viaf/251603995
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
776	0	8	_iEdición impresa: _z9783319764955
776	0	8	_iEdición impresa: _z9783319764979
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-76496-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
490	0		_aBiomedical and Life Sciences (Springer-11642)
942			_2lcc
988			_aEBSPRINGER_2018
998			_aSI _a_alco _a_vill _b02/2019 _cm _dz _ek _feng _ggw _h0
999			_c100647 _d100647 _x1